Literature DB >> 24770758

Insulin-like growth factors (IGF), IGF-binding proteins (IGFBP), and vascular endothelial growth factor (VEGF) in blood serum of patients with colorectal cancer.

N E Kushlinskii1, E S Gershtein, A A Nikolaev, V V Delektorskaya, E A Korotkova, E K Dvorova, O I Kostyleva.   

Abstract

Serum levels of insulin-like growth factors (IGF-1 and IGF-2), IGF-binding proteins (IGFBP-1, IGFBP-2, and IGFBP-3) and vascular endothelial growth factor (VEGF) were measured by standard ELISA technique in 95 primary colorectal cancer patients and 48 healthy individuals. Significant increase in serum levels of IGF-1, IGFBP-2, and VEGF and decrease in IGFBP-3 level were demonstrated in patients in comparison with the control group; in male patients, serum level of IGF-2 was also increased. Sensitivity of IGF-1 as the prospective diagnostic marker of colorectal cancer was 80% and specificity was 75% at the threshold level of 140 ng/ml. Serum levels of IGF-1 significantly decreased with age in both patients and healthy donors, but in patients, this correlation was much weaker. These parameters did not correlate with the main clinical and morphological indices, such as dissemination, localization, and histological structure of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24770758     DOI: 10.1007/s10517-014-2425-0

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  12 in total

1.  Circulating insulin-like growth factor-related biomarkers: Correlates and responses to calcium supplementation in colorectal adenoma patients.

Authors:  Caroline Y Um; Veronika Fedirko; W Dana Flanders; Christine Höflich; Elisa Wirthgen; Roberd M Bostick
Journal:  Mol Carcinog       Date:  2017-05-24       Impact factor: 4.784

2.  Novel serum markers HSP60, CHI3L1, and IGFBP-2 in metastatic colorectal cancer.

Authors:  Michal Vocka; Daniel Langer; Vladimir Fryba; Jaromir Petrtyl; Tomas Hanus; Marta Kalousova; Tomas Zima; Lubos Petruzelka
Journal:  Oncol Lett       Date:  2019-09-26       Impact factor: 2.967

3.  IGFBP-3 reduces eNOS and PKCzeta phosphorylation, leading to lowered VEGF levels.

Authors:  Qiuhua Zhang; Youde Jiang; Jena J Steinle
Journal:  Mol Vis       Date:  2015-05-22       Impact factor: 2.367

4.  Circulating VEGF as a biomarker for diagnosis of ovarian cancer: a systematic review and a meta-analysis.

Authors:  Bin Liang; Qun He; Liansheng Zhong; Shaocheng Wang; Zhongcheng Pan; Tianjiao Wang; Yujie Zhao
Journal:  Onco Targets Ther       Date:  2015-05-15       Impact factor: 4.147

5.  Higher IGFBP-1 to IGF-1 serum ratio predicts unfavourable survival in patients with nasopharyngeal carcinoma.

Authors:  Xinwei Feng; Jianhua Lin; Shan Xing; Wanli Liu; Ge Zhang
Journal:  BMC Cancer       Date:  2017-01-31       Impact factor: 4.430

Review 6.  Biochemical Markers of Colorectal Cancer - Present and Future.

Authors:  Wojciech Jelski; Barbara Mroczko
Journal:  Cancer Manag Res       Date:  2020-06-22       Impact factor: 3.989

Review 7.  Prediction of the treatment response in ovarian cancer: a ctDNA approach.

Authors:  Mina Sharbatoghli; Somayeh Vafaei; Hamidreza Aboulkheyr Es; Mohsen Asadi-Lari; Mehdi Totonchi; Zahra Madjd
Journal:  J Ovarian Res       Date:  2020-10-19       Impact factor: 4.234

Review 8.  Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment.

Authors:  Kunal Amratlal Lodhia; Piyawan Tienchaiananda; Paul Haluska
Journal:  Front Oncol       Date:  2015-07-08       Impact factor: 6.244

9.  Correlation Between IGFs-Related Proteins Expression and Incidence of Colorectal Cancer in Diabetic Patients and Related Mechanisms.

Authors:  Xu Han; Sufang Hou; Aige Yang
Journal:  Med Sci Monit       Date:  2016-03-15

Review 10.  Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer-From Basic Research to Potential Clinical Applications.

Authors:  Aldona Kasprzak; Agnieszka Adamek
Journal:  Int J Mol Sci       Date:  2019-10-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.